|
Jul 26
|
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer
|
|
Dec 21
|
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
|
|
Dec 8
|
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
|